Journal
INNATE IMMUNITY
Volume 17, Issue 1, Pages 3-15Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1753425909347508
Keywords
MDP; LPS; SOCS1; macrophage; inflammatory cytokines
Categories
Funding
- Tohoku University Graduate School of Dentistry
Ask authors/readers for more resources
Muramyldipeptide (MDP), the minimum essential structure responsible for the immuno-adjuvant activity of peptidoglycan, is recognized by intracellular nuclear-binding oligomerization domain 2 (NOD2). Muramyldipeptide enhances the activities of lipopolysaccharide (LPS), but the mechanism underlying this effect is unclear. Here, we obtained evidence that intravenously injected MDP augments LPS-induced hypothermia in wild-type mice, but not in mice deficient in interleukin (IL)-1 alpha/beta and/or tumor-necrosis factor (TNF)-alpha. Muramyldipeptide also: (i) increased pro-IL-1 beta in tissues, but did not increase IL-1 beta in serum (since caspase-1 was not activated by MDP); (ii) down-regulated the expression of suppressor of cytokine signaling 1 (SOCS1; a negative-feedback regulator of LPS-induced signaling); and (iii) augmented the LPS-induced production of TNF-alpha, IL-12 p40, and interferon (IFN)-gamma. Moreover, by performing in vivo and in vitro experiments, we obtained evidence that macrophages were involved in these effects of MDP. These results suggest that two different mechanisms may underlie the augmenting effect of MDP: namely, stimulation of pro-IL-1 beta production by, and down-regulation of SOCS1 in, macrophages. We consider that this work may help to elucidate the pathogenesis of mixed bacterial infections, including septic shock and multiple organ dysfunction syndrome (MODS).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available